Development of possible COVID-19 vaccine for elderly | ||
| Microbes and Infectious Diseases | ||
| Article 3, Volume 2, Issue 1, February 2021, Pages 5-6 PDF (270.27 K) | ||
| Document Type: Letter to the Editor | ||
| DOI: 10.21608/mid.2020.48853.1083 | ||
| Authors | ||
| Siukan Law* 1; Albert Wingnang Leung2; Chuanshan Xu3 | ||
| 1Department of Science, School of Science and Technology, The Open University of Hong Kong, Ho Man Tin, Kowloon, Hong Kong | ||
| 2School of Graduate Studies, Lingnan University, Tuen Mun, Hong Kong | ||
| 3Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China | ||
| Abstract | ||
| According to the Centers for Disease Control and Prevention in the USA, reported that the risk of infection with COVID-19 increases with age, especially in older adults, and those who suffered from other immune diseases or continuously taking medications. Some elderlies are immunosenescence due to the decline in an immune system’s functionality with age, thus, the COVID-19 vaccine may not be effective for them and it is big trouble. How does the COVID-19 vaccine induce robust immune responses in the elderly? In general, the number of naive T cells decreases while age increases. This makes the B cells lose their function and less attachment on the antibodies surface lead unable to defend and target the virus for destruction causing it cannot engulf the virus and nor cause inflammation to remove the infected cells. Therefore, it is not easy to develop a suitable COVID-19 for the elderly. Pawelec et al. indicated that it must have a biomarker in the elderly COVID-19 vaccine. There is an investigation of the Yellow Fever vaccination. (To be continued)... | ||
| Keywords | ||
| COVID-19 vaccine; Elderly; Robust immune responses | ||
|
Statistics Article View: 527 PDF Download: 493 |
||
